AIM ImmunoTech Reports $13.96 Million Net Loss for Fiscal Year 2025

AIM ImmunoTech Inc. reported a net loss of approximately $13.96 million for the fiscal year ending December 31, 2025, a decrease of 19% from the previous year's loss of $17.32 million. This reduction in net loss was attributed to a significant decrease in general and administrative expenses, which fell by $6.01 million, and a reduction in research and development costs by $2.27 million. The company also noted a gain from investments of $110,000 and a positive change in the fair value of warrants amounting to $186,000. However, these improvements were partially offset by losses recognized from warrant issuance totaling $3.98 million and a decrease in interest and other income by $2.01 million.

In terms of revenue, AIM generated $88,000 from its Ampligen Cost Recovery Program, down from $170,000 in 2024, primarily due to fluctuations in patient participation. The company’s interest and other income also decreased to $3.18 million from $5.19 million in the prior year, with a notable contribution from a settlement agreement regarding disputed legal fees. Production costs increased to $128,000 from $31,000, reflecting higher expenses related to Ampligen manufacturing. Research and development expenses totaled $3.92 million, down from $6.20 million, while general and administrative expenses were significantly reduced to $7.70 million from $13.71 million.

AIM ImmunoTech has made strategic decisions to focus on the development of its lead product, Ampligen, particularly for the treatment of late-stage pancreatic cancer, which is seen as a lucrative market opportunity. The company has established a partnership with Thermo Fisher Scientific to design a Phase 3 clinical trial for Ampligen in this indication. Additionally, AIM is exploring the potential of Ampligen as a treatment for COVID-19 and related conditions, with ongoing studies indicating promising antiviral properties.

As of December 31, 2025, AIM reported a working capital deficit of approximately $2.93 million and stockholders' equity below the minimum requirement for continued listing on the NYSE American. The company has submitted a plan to regain compliance by June 11, 2026, and is actively seeking additional funding to support its operations and clinical trials. AIM's management has expressed concerns about the company's ability to continue as a going concern if it cannot secure the necessary capital. The company had approximately $3.05 million in cash and cash equivalents at year-end, indicating a need for further financing to meet operational needs.

Looking ahead, AIM ImmunoTech aims to leverage its research and development efforts to advance Ampligen through clinical trials and regulatory approvals. The company is also focused on expanding its market presence, particularly in Argentina, where Ampligen is approved for the treatment of severe Chronic Fatigue Syndrome. AIM's future success will depend on its ability to navigate regulatory challenges, secure funding, and effectively market its products in a competitive landscape.